FDA won't DQ doc over data submissions; Basilea gives isavuconazole update

@FierceBiotech: Acceleron inks $498M pact with Shire for lead muscle drug. Article  Follow @FierceBiotech

 @JohnCFierce:New leak from BLMB: Genzyme investors demanding $75 from Sanofi. Absolutely, positively, lowest possible bid. Sure.  Article | Follow @JohnCFierce 

> Federal regulators decided not to disqualify a prominent North Side HIV doctor whose clinic submitted fictitious data in a drug trial. News

> Basilea Pharmaceutica announced today that, in agreement with its partner Astellas, the initiation of study centers in the isavuconazole Phase III clinical program will be deferred to year-end or early 2011. Availability of Phase III data continues to be anticipated by 2013. Basilea release

> Bristol-Myers Squibb Company is commencing today, through its wholly owned subsidiary Zeus Acquisition Corporation, a cash tender offer to purchase all outstanding shares of common stock of ZymoGenetics. Bristol-Myers Squibb announced on Tuesday its intent to acquire ZymoGenetics. BMS release

> The hedge funds think Arena Pharmaceuticals will fail. That's the consensus opinion emerging from an informal email poll taken this week, which asked healthcare buy-side investors, mostly biotech-focused hedge funds, to handicap the Sept. 16 FDA advisory panel that will review Arena's obesity drug lorcaserin. Article

> With regulations covering biosimilar medicines falling into place around the world, there is a need to reach global agreement on criteria and guidelines for such products, say European generics industry leaders. Item

> The US-India Business Council will embark on a life sciences executive mission to coincide with the Biotechnology Industry Organisation's first annual international partnering conference in Hyderabad Sep 21-22. Story

> The pharmaceutical, biotech and medical device industries stand to benefit from President Obama's proposal to expand the research and development tax credit, according to Wall Street analysts. News

> Eurand has announced the resignation of CFO Mario Crovetto, effective January 2011. Eurand release

> Edimer Pharmaceuticals and CMC Biologics have executed a manufacturing contract to support the development of EDI200, a clinical-stage recombinant protein for the treatment of X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), a rare genetic disease with orphan designation in the USA and Europe. Edimer/CMC release

And Finally... Antimicrobial peptides from the skin of frogs may protect against life-threatening, multidrug-resistant infections such as Pseudomonas aeruginosa say researchers from Italy. They detail their findings in the September 2010 issue of the journal Antimicrobial Agents and Chemotherapy. Release

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.